Amyloid plaque aggregation inhibitors and diagnostic imaging agents

Abstract

This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.

What is claimed is: 
     
       1. A compound of Formula III: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, wherein
 R 3  is Br, I, F,  125 I,  131 I,  123 I,  18 F,  76 Br,  77 Br of or Sn(alkyl) 3 ; and 
 R 1  and R 2  are independently hydrogen, C 1-4  alkyl, C 2-4  aminoalkyl, C 1-4  haloalkyl, haloarylalkyl, or R 1  and R 2  are taken together with the nitrogen to which they are attached to form a 5- to 7-member heterocyclic ring optionally having O, S, or NR 5  in said ring, where 
 R 5  is hydrogen or C 1-4  alkyl. 
 
     
     
       2. A The compound of  claim 1 , wherein R 3  is  125 I,  131 I,  123 I,  18 F,  76 Br, or  77 Br. 
     
     
       3. A The compound of  claim 2 , wherein:
 R 1  and R  2  are independently selected from hydrogen, C 1-4  alkyl, C 1-4  haloalkyl, or 4-fluorobenzyl. 
 
     
     
       4. A The compound of  claim 1 , wherein:
 R 5 R 3  is  123 I or  125 I; and 
 R 1  and R 2  are both methyl. 
 
     
     
       5. A The compound of  claim 1 , wherein:
 R 3  is Sn(alkyl) 3 ; and 
 R 1  and R 2  are independently hydrogen, C 1-4  alkyl, C 1-4  haloalkyl, or 4-fluorobenzyl. 
 
     
     
       6. A The compound of  claim 5 , wherein R 1  and R 2  are C 1-4  alkyl. 
     
     
       7. A The compound of  claim 6 , wherein R 1  and R 2  are methyl. 
     
     
       8. A compound of Formula III′: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, wherein
 A, B, and D are CH or N, 
 provided that no more than two of A, B, and D is N; 
 R 3  is Br, I, F,  125 I,  131 I,  123 I,  18 F,  76 Br,  77 Br, haloalkyl, Sn(alkyl) 3  or —L—Ch; 
 R 1  and R 2  are independently hydrogen, C 1-4  alkyl, C 2-4  aminoalkyl, C 1-4  haloalkyl, haloarylalkyl, —L—Ch, or R 1  and R 2  are taken together with the nitrogen to which they are attached to form a 5- to 7-member heterocyclic ring optionally having O, S or NR 5  in said ring, where
 R 5  is hydrogen or C 1-4  alkyl; 
 L is a covalent bond or linking group, such as —(CH 2 ) n —, or —(CH 2 ) n —C(O)— 
 where
 n is 0-5; and 
 Ch is a tetradentate ligand capable of complexing with a metal; 
 with the proviso that only one of R 1 , R 2 , and R 3  can be is —L—Ch. 
 
 
 
     
     
       9. A The compound of  claim 8 , wherein A and B are CH; and D is N. 
     
     
       10. A The compound of  claim 8 , wherein A and D are CH; and B is N. 
     
     
       11. A The compound of  claim 8 , wherein B and D are CH; and A is N. 
     
     
       12. A The compound of  claim 9 , wherein R 1  and R 2  are independently hydrogen or C 1-4  alkyl. 
     
     
       13. A The compound of  claim 12 , wherein R 1  and R 2  are both methyl. 
     
     
       14. A The compound of  claim 13 , wherein R 3  is Br, I, F,  125 I,  131 I,  123 I,  18 F,  76 Br,  77 Br,  18 F/fluoro(C 1-5 )alkyl or Sn(alkyl) 3 . 
     
     
       15. A The compound of  claim 14 , wherein R 3  is  18 F/fluoromethyl,  18 F/fluoroethyl,  18 F/fluoropropyl,  18 F/fluorobutyl, or  18 F/fluoropentyl. 
     
     
       16. A The compound of  claim 9 , wherein R 3  is L-Ch. 
     
     
       17. A The compound of  claim 16 , wherein Ch is selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
     
     
       18. A The compound of  claim 17 , wherein Ch is: 
       
         
           
           
               
               
           
         
       
     
     
       19. A The compound of  claim 18 , wherein R 1  and R 2  are independently hydrogen or C 1-4  alkyl. 
     
     
       20. A The compound of  claim 19 , wherein R 1  and R 2  are both methyl. 
     
     
       21. A pharmaceutical composition, comprising a compound of  claim 1  and a pharmaceutically acceptable excipient or diluent. 
     
     
       22. A diagnostic composition for imaging amyloid deposits, comprising a radiolabeled compound of  claim 2  and a pharmaceutically acceptable excipient or diluent. 
     
     
       23. A method of inhibiting reducing amyloid plaque aggregation in a mammal, comprising administering a composition of  claim 21  in an amount effective to inhibit reduce amyloid plaque aggregation. 
     
     
       24. A method of imaging amyloid deposits, comprising:
 a. introducing into a mammal a detectable quantity of a diagnostic composition of  claim 22 ; and 
 b. allowing sufficient time for the radiolabeled compound to become associated with amyloid deposits; and 
 c. detecting the radiolabeled compound associated with one or more amyloid deposits.